Inventor · disambiguated record
E. Scott Priestley
Also filed as: PRIESTLEY E S · PRIESTLEY E SCOTT
7 granted patents·2 pending applications·242 citations·filing 1998–2024
88Inventor score
Files withBRISTOL MYERS SQUIBB CO5BRISTOL MYERS SQUIBB PHARMA CO1HERPIN TIMOTHY1ONCOPIA THERAPEUTICS INC D/B/A/ SK LIFE SCIENCE LABS1SCRIPPS RESEARCH INST1
Top patents by PatentIndex Score
9 records- 0195US6939854B2Peptide inhibitors of hepatitis C virus NS3 proteaseBRISTOL MYERS SQUIBB PHARMA CO·Filed 2004·Granted Sep 6, 2005·65 cites·3 claims
- 0295US6846806B2Peptide inhibitors of Hepatitis C virus NS3 proteinBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Jan 25, 2005·85 cites·1 claims
- 0389US7122627B2Lactam inhibitors of Hepatitis C virus NS3 proteaseBRISTOL MYERS SQUIBB CO·Filed 2001·Granted Oct 17, 2006·35 cites·25 claims
- 0485US7247654B23,4-disubstituted benzamidines and benzylamines, and analogues thereof, useful as serine protease inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Jul 24, 2007·17 cites·20 claims
- 0576US7122559B2Phenylglycine derivatives useful as serine protease inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2004·Granted Oct 17, 2006·8 cites·32 claims
- 0674US6846838B2Ureido-substituted aniline compounds useful as serine protease inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2003·Granted Jan 25, 2005·5 cites·22 claims
- 0773US6120997ANucleic acid binders having an hydroxyamine motifSCRIPPS RESEARCH INST·Filed 1998·Granted Sep 19, 2000·27 cites·1 claims
- 0865US2025114345A1Compounds and compositions as cbp/p300 degraders and uses thereofONCOPIA THERAPEUTICS INC D/B/A/ SK LIFE SCIENCE LABS·Filed 2024·Application pending·0 cites
- 0955US2006173057A1Methods of treating factor VIIa-associated conditions with compounds having an amine nucleusHERPIN TIMOTHY·Filed 2006·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when E. Scott Priestley files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →